Alterity Widens Half-Year Loss but Lifts Asset Backing on Higher Interest Income

Alterity Therapeutics ( (AU:ATH) ) just unveiled an announcement.

Alterity Therapeutics reported a sharp increase in half-year revenue to A$909,750 for the six months to 31 December 2025, driven entirely by higher interest income on its bank balances, while remaining a pre-revenue biotech with no dividend payments. The company’s net loss widened 34% to A$9.6 million compared with the prior corresponding period, but net tangible asset backing rose to 0.50 cents per share from 0.14 cents, signaling a stronger balance sheet despite ongoing losses and unchanged corporate structure.

Management noted that the detailed drivers of the loss are outlined in its review of operations, and the interim financial statements have been reviewed by an independent auditor, offering additional assurance to investors. With no changes in controlled entities and no distributions declared, the update highlights Alterity’s continued focus on funding and executing its development programs while absorbing significant operating expenses typical of early-stage biotechnology companies.

The most recent analyst rating on (AU:ATH) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.

More about Alterity Therapeutics

Alterity Therapeutics Limited is a biotechnology company focused on developing therapeutic treatments, likely within the pharmaceutical or life sciences sector, as indicated by its R&D-driven cost structure and lack of product revenue. The company currently generates income primarily from interest on cash reserves rather than commercial operations, underscoring its status as a pre-revenue or early-stage clinical developer reliant on external funding.

Average Trading Volume: 6,636,207

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$87M

For detailed information about ATH stock, go to TipRanks’ Stock Analysis page.